▼Glycopyrronium for COPD

▾Glycopyrronium powder for inhalation (Seebri Breezhaler-Novartis) is a long-acting muscarinic receptor antagonist (LAMA), licensed as a maintenance bronchodilator treatment to relieve symptoms in adults with chronic obstructive pulmonary disease (COPD).¹ This is the third long-acting agent that has recently been licensed in the UK for use in people with COPD (see ▾Indacaterol for COPD² and ▾Aclidinium for COPD?³). The company's promotional material claims that 'Seebri is a once daily LAMA which supports cost effective prescribing at all stages of COPD'.⁴ In this article we review the evidence for glycopyrronium and assess its place in the management of COPD.